Please assess the completion status of the following clinical trial:

Trial Title: Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female adults aged \> 40 years with a diagnosis of COPD~* Current smokers or ex-smokers~* A post-bronchodilator FEV1 \< 50% of the predicted normal value and a post-bronchodilator FEV1/FVC ratio \< 0.7 at least 10-15 minutes after 4 puffs (4 x 100 µg) of salbutamol pMDI~* At least one exacerbation in the 12 months preceding the screening visit~Exclusion Criteria:~* Pregnant or lactating women~* Diagnosis of asthma, history of allergic rhinitis or atopy~* Patients treated for exacerbations in the 4 weeks prior to screening visit~* Patients treated with non-cardioselective ß-blockers in the month preceding the screening visit~* Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as Pro Re Nata~* Patients requiring long term ( at least 12 hours daily) oxygen therapy for chronic hypoxemia~* Known respiratory disorders other than COPD~* Patients who have clinically significant cardiovascular condition

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHF 5993 100/6/12.5 µg (Type: EXPERIMENTAL): Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
- Symbicort Turbuhaler 160/4.5 µg (Type: ACTIVE_COMPARATOR): Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)

Based on this trial design, predict the completion outcome and termination type (if applicable).